window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

extracellular vesicles

  • Advanced Therapies,Drug Discovery & Development

    Spot Biosystems reports early clinical evidence for non-viral dystrophin delivery in Duchenne muscular dystrophy

    Spot Biosystems has emerged from stealth with $40 million in [...]

    June 18, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    Ciloa lands €6.5 million (£5.7 million) government backing to develop novel obesity and diabetes bio-drug

    Ciloa, a pioneer in bioengineering extracellular vesicles (EVs) for innovative [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top